The DLEC1 Knockout HAP1 Polyclonal Cells consist of a polyclonal population of HAP1 cells engineered via CRISPR/Cas9 to disrupt the DLEC1 gene, generating a loss-of-function model of this critical tumor suppressor. The polyclonal format provides a heterogeneous pool of edited alleles, reflecting the genetic diversity generated by non-homologous end joining repair. This product is intended for researchers requiring a robust system to evaluate DLEC1-dependent phenotypes without single-cell cloning bottlenecks.
HAP1 is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia cell line. Its haploid karyotype, with only one copy of most chromosomes, enables efficient gene disruption and clear genotype?Cphenotype correlations. The line retains key signaling pathways relevant to cancer biology, making it a highly tractable model for functional genomics and knockout studies. The absence of a second allele eliminates confounding compensation effects, providing a simplified genetic background for dissecting tumor suppressor functions.
DLEC1 acts as a tumor suppressor by negatively regulating cell proliferation and promoting apoptosis. Mechanistically, DLEC1 stabilizes p53 and suppresses both the AKT and ERK signaling cascades, leading to cell cycle arrest and programmed cell death. The gene is frequently silenced in multiple cancers through promoter hypermethylation mediated by DNA methyltransferases such as DNMT1. DLEC1 interacts with p53 and DNMT1, and its downstream effects involve upregulation of cell cycle inhibitors p21 and p27, activation of pro-apoptotic factors BAX and PUMA, and inhibition of NF-??B signaling. These interactions position DLEC1 at a nexus of pathways controlling growth suppression and stress responses.
In the HAP1 haploid background, disruption of DLEC1 provides a clean loss-of-function system that mimics its epigenetic inactivation observed in lung, esophageal, breast, renal, and gastric carcinomas. Removal of DLEC1 allows unambiguous assessment of its role in restraining proliferation and survival signaling. Key readouts include derepression of phospho-AKT and phospho-ERK levels, resistance to apoptosis, and enhanced colony formation. This model is therefore well-suited to dissect DLEC1??s contribution to tumorigenesis and to study the consequences of its loss in a defined genetic context.
These polyclonal knockout cells are ideal for a range of applications in cancer biology, including functional studies of tumor suppressor genes, epigenetic silencing mechanisms, and drug target validation for reactivation therapy. Researchers can investigate DLEC1 re-expression using demethylating agents or HDAC inhibitors, and assess phenotypic rescue. Representative assays include western blotting for DLEC1 and downstream signaling proteins, RT-qPCR for transcript quantification, cell proliferation and colony formation assays, apoptosis detection via Annexin V staining, and phospho-signaling profiling. The polyclonal nature supports pooled screening approaches while maintaining biological heterogeneity. For additional information, please contact Ascent Research.
